COR vs GIPL vs BTSG Stock Comparison

Cencora, Global Innovative Platforms and BrightSpring Health Services Prices as of Oct 28, 2026 Peers: Industry group
COR Cencora, Inc.
$324.43 +6.8% 1M -3.3% 1Y
Market cap
$63.75B
P/E
24.3x
Revenue (TTM)
$332.77B
Div. yield
0.01%
Drug Distribution Healthcare
6 wins

Head to Head

11 decided of 12

Cencora leads on 6 of the 12 questions below (Cencora 6, BrightSpring Health Services 4, Global Innovative Platforms 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCORGIPLBTSGLeader
Larger companyMarket capitalisation $63.75B $24.88M $12.53B COR
Cheaper on earningsLower P/E, profitable companies only 24.3x -36.0x 34.2x COR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.0x — 34.4x COR
Faster revenue growthRevenue growth, trailing twelve months +5.1% — +26.4% BTSG
More profitableNet margin, trailing twelve months 0.8% -361.7% 2.5% BTSG
Better return on capitalReturn on invested capital 14.4% — 8.6% COR
Less leveragedLower net debt / EBITDA 2.2x 0.4x 2.6x GIPL
Higher dividend yieldTrailing dividend yield 0.01% — 0.00% –
Better 1-year returnPrice return, last 12 months -3.3% -37.5% +74.9% BTSG
Better 5-year returnAnnualised price return, 5 years +21.6%/yr -36.9%/yr — COR
Less volatileAnnualised volatility, 1 year 32.7% 270.9% 44.6% COR
Higher overall scoreMean of the five percentile scores vs peers 53/100 55/100 64/100 BTSG

Percentile Scorecard

CORGIPLBTSG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCORGIPLBTSG
Valuation 63 #10 of 25 61 #244 of 625 66 #32 of 92
Growth 74 #7 of 24 27 #439 of 602 93 #7 of 87
Profitability 57 #11 of 24 39 #334 of 549 58 #37 of 86
Financial Health 24 #20 of 26 98 #12 of 654 40 #59 of 97
Shareholder Returns 47 #9 of 16 50 #184 of 367 63 #21 of 55
Overall 53 55 64
  • COR ranked among 27 companies in Healthcare Payers and Distributors
  • GIPL ranked among 672 companies in Pharmaceuticals and Biotechnology
  • BTSG ranked among 102 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCORGIPLBTSGSPY
1 month +6.8%0.0%+5.2% +0.9%
3 months +1.8%0.0%-14.3% +5.9%
6 months +4.2%-3.8%+23.5% +8.5%
Year to date -3.9%+354.5%+58.8% +13.3%
1 year -3.3%-37.5%+74.9% +12.4%
3 years +72.9%-52.4%— +88.1%
3 years, per year +20.0%-21.9%— +23.5%
5 years +165.9%-90.0%— +68.2%
5 years, per year +21.6%-36.9%— +11.0%
10 years +369.2%-79.2%— +263.4%
10 years, per year +16.7%-14.5%— +13.8%

Risk

MeasureCORGIPLBTSGSPY
Volatility, 1Y 32.7%270.9%44.6% 12.7%
Downside volatility, 1Y 39.5%—51.5% 12.7%
Beta vs S&P 500, 1Y -0.152.261.30 1.00
Return / volatility, 1Y -0.10-0.141.68 0.98
Max drawdown, 5Y -32.6%-98.0%-35.6% -25.4%
From 52-week high -13.4%-49.5%-18.4% -0.9%
52-week high $374.75$0.99$72.91 $779.14
52-week low $252.74$0.11$31.36 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCORGIPLBTSG
P/E now vs peer median 23.9xmedian 23.9x -36.0xmedian 17.4x 33.5xmedian 25.6x
P/S now vs peer median 0.2xmedian 0.3x 132.9xmedian 9.1x 0.8xmedian 1.6x
EV/EBITDA now vs peer median 17.2xmedian 12.7x -39.5xmedian 17.1x 21.6xmedian 16.3x
P/FCF now vs peer median 15.2xmedian 15.4x -32.5xmedian 19.0x 29.2xmedian 21.3x
P/B now vs peer median 19.1xmedian 2.5x 46.8xmedian 2.2x 5.7xmedian 3.3x
PEG now vs peer median 1.34median 1.34 -0.57median 0.34 —median 0.68

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCORGIPLBTSG
Revenue $332.77B $187.20K $14.37B
Gross profit $13.22B – $1.78B
Operating income $3.04B -$677.04K $447.80M
Net income $2.65B -$677.04K $365.85M
Free cash flow $4.06B -$766.04K $402.35M
R&D – $377.99K –
EPS (diluted) $13.53 $-0.02 $1.66
Cash & equivalents $2.82B $244.24K $550.38M
Total debt $11.72B $8.62K $2.19B
Shares (diluted) 193.94M 44.54M 220.28M
Enterprise value $52.65B $24.27M $10.86B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCORGIPLBTSG
P/E 23.9x -36.0x 33.5x
P/FCF 15.2x -32.5x 29.2x
P/Operating cash flow 12.8x -35.0x 23.2x
P/S 0.2x 132.9x 0.8x
P/B 19.1x 46.8x 5.7x
P/Tangible book -23.0x 47.1x 7.7x
EV/EBITDA 17.2x -39.5x 21.6x
EV/EBIT 23.3x -36.4x 29.9x
EV/Revenue 0.2x 131.6x 0.9x
EV/FCF 17.4x -32.2x 33.3x
EV/Operating cash flow 14.7x -34.7x 26.4x
PEG (3Y EPS CAGR) 1.34 -0.57 –

Growth

14 metrics
MetricCORGIPLBTSG
Revenue growth (1Y) 5.1% – 26.4%
Revenue CAGR (3Y) 9.4% – –
Gross profit growth (1Y) 20.0% – 29.4%
Gross profit CAGR (3Y) 15.0% – –
Operating income growth (1Y) 11.1% -20.9% 143.5%
Operating income CAGR (3Y) 9.5% -51.6% –
Net income growth (1Y) 38.9% -20.9% 472.6%
Net income CAGR (3Y) 16.2% -51.6% –
EPS growth (1Y) 39.3% -9.8% 448.6%
EPS CAGR (3Y) 17.9% 63.5% –
Operating cash flow growth (1Y) 176.7% 15.8% 88.6%
Operating cash flow CAGR (3Y) 14.1% -96.8% –
Free cash flow growth (1Y) 255.7% 9.2% 110.5%
Free cash flow CAGR (3Y) 13.3% -101.8% –

Profitability

14 metrics
MetricCORGIPLBTSG
Gross margin 4.0% – 12.4%
EBITDA margin 1.2% -333.4% 4.3%
Operating margin 0.9% -361.7% 3.1%
Pretax margin 1.1% -361.7% 2.1%
Net margin 0.8% -361.7% 2.5%
FCF margin 1.2% -409.2% 2.8%
Operating cash flow margin 1.4% -379.8% 3.5%
Return on equity 77.4% -120.8% 18.2%
Return on assets 3.2% -119.7% 6.0%
Return on invested capital 14.4% – 8.6%
Return on capital employed 12.9% -121.4% 9.9%
Asset turnover 4.0x 0.3x 2.4x
Cash conversion (OCF / net income) 1.8x 1.1x 1.4x
Stock comp / revenue 0.0% – 0.4%

Financial Health

11 metrics
MetricCORGIPLBTSG
Debt / assets 14.0% 1.0% 36.6%
Debt / equity 3.6x 0.0x 1.1x
Net debt / EBITDA 2.2x 0.4x 2.6x
Debt / FCF 2.9x 0.0x 5.4x
Liabilities / assets 96.1% 1.4% 65.8%
Equity / assets 3.9% 98.6% 34.2%
Interest coverage – – 2.9x
Current ratio 0.9x 34.7x 1.6x
Quick ratio 0.5x 33.2x 1.1x
Cash ratio 0.0x 31.3x 0.4x
Altman Z-score 4.65 1,908 4.63

Shareholder Returns

7 metrics
MetricCORGIPLBTSG
Dividend yield 0.7% – –
Net buyback yield 1.6% -3.2% 0.6%
Shareholder yield 2.3% -3.2% 0.6%
Payout ratio (earnings) 17.7% – –
Payout ratio (FCF) 11.5% – –
Dividend growth (1Y) 8.7% – –
Dividend CAGR (3Y) 5.7% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCORGIPLBTSG
Forward P/E 19.0xFY2026 – 34.4xFY2026
EPS, next fiscal year $17.08FY2026 – $1.73FY2026
EPS growth, next FY +6.7%FY2026 – +73.0%FY2026
EPS growth, the year after +11.8% – +42.2%
Revenue, next fiscal year $328.56BFY2026 – $16.01BFY2026
Revenue growth, next FY +2.2%FY2026 – +24.0%FY2026
Revenue growth, the year after -0.3% – +1.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCORGIPLBTSG
Held by institutions 94.7% – 100.0%
Institutions holding 1,343 – 421
Change in shares held, QoQ +15.7% – -0.7%
Institutions buying 542 – 309
Institutions selling 610 – 83
Buyers to sellers 0.89 – 3.72

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CORGIPLBTSG
COR 1.00 0.00 0.06
GIPL 0.00 1.00 0.08
BTSG 0.06 0.08 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, COR, GIPL and BTSG?

Cencora (COR) is the largest by market capitalisation: Cencora (COR) $63.75B, Global Innovative Platforms (GIPL) $24.88M, BrightSpring Health Services (BTSG) $12.53B.

Which stock is cheaper, COR, GIPL and BTSG?

Cencora (COR) trades on the lowest price-to-earnings ratio (Cencora (COR) 24.3x, Global Innovative Platforms (GIPL) -36.0x, BrightSpring Health Services (BTSG) 34.2x). On next year's consensus earnings, Cencora (COR) is cheapest (Cencora (COR) 19.0x, BrightSpring Health Services (BTSG) 34.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

BrightSpring Health Services (BTSG) grew revenue fastest over the trailing twelve months: Cencora (COR) +5.1%, BrightSpring Health Services (BTSG) +26.4%.

Which company is more profitable?

BrightSpring Health Services (BTSG) has the highest net margin (Cencora (COR) 0.8%, Global Innovative Platforms (GIPL) -361.7%, BrightSpring Health Services (BTSG) 2.5%). On return on invested capital, Cencora (COR) leads (Cencora (COR) 14.4%, BrightSpring Health Services (BTSG) 8.6%).

Which stock has performed better?

Over the past year BrightSpring Health Services (BTSG) returned the most: Cencora (COR) -3.3%, Global Innovative Platforms (GIPL) -37.5%, BrightSpring Health Services (BTSG) +74.9%. Over five years, Cencora (COR) compounded fastest (Cencora (COR) +21.6%/yr, Global Innovative Platforms (GIPL) -36.9%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Cencora (COR) 0.01%, BrightSpring Health Services (BTSG) 0.00%. Global Innovative Platforms (GIPL) and BrightSpring Health Services (BTSG) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Cencora (COR) has been the steadiest (Cencora (COR) 32.7%, Global Innovative Platforms (GIPL) 270.9%, BrightSpring Health Services (BTSG) 44.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, COR, GIPL and BTSG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cencora (COR) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.